top of page

PBG BioPharma Inc. Receives Cannabis 2.0 Sales Amendment to Health Canada Licence

Updated: May 24, 2023

LEDUC, AB – March 1, 2022 – PBG BioPharma Inc. (“PBG” or the “Company”), a Phytochemical Biopharmaceutical Group Company, is pleased to announce that the Company has received an amendment to its Health Canada licence that permits the company to supply extracts, edibles, and topicals directly to provincial distributors, retailers in select provinces, and licensed sellers of medical cannabis.

Dr. Jacqueline Shan, PBG BioPharma’s President and CEO, stated, “This is another milestone for PBG, allowing us to expand beyond selling API cannabis products to our B2B customers and into the broader consumer market. We are excited to be able launch our branded cannabis products onto store shelves, as well as fully realize our vision of becoming a one-stop-shop for retail companies looking to develop and launch their own line of products.”

This sales amendment is the latest in a slew of licences for the company, including most recently a Controlled Substances Dealer’s Licence for the processing and manufacturing of psilocin and psilocybin.


PBG BioPharma is a vertically integrated biopharmaceutical company focusing on the research and development, testing and manufacturing of nutraceuticals and biopharmaceuticals, including science-based natural health, cannabis and psychedelic products. Using its proprietary GenBioChem® Triple Fingerprinting Technology platform, the Company takes a pharmaceutical approach to its product development, testing and manufacturing process for premium quality. PBG has constructed a 25,000 square foot state-of-the-art biopharmaceutical production and lab facility, and amassed a large licence portfolio, including a Cannabis Standard Processing Licence with Sales Amendment Licence, Cannabis Analytical Licence, 3 Cannabis Research Licences, GMP NHP Site Licence, Controlled Substances Dealer’s Licence, and ISO 10725 certification, which will allow the company to provide point-to-point services to its industrial partners from research and development to manufacturing and testing to end consumers. PBG is currently conducting research and development in the areas of immunotherapy, broad-spectrum anti-viral therapy, neuropathic pain and other neurological disorder management, and psychedelics for mental health disorders. PBG also has several product lines on the market, including GenBioChem® line natural health products, CannFx® brand cannabis products and various plant-based active pharmaceutical ingredients such as 100% pure CBD isolates.


bottom of page